Cost-Consequence Analysis of Switching from an Oral Antipsychotic to Long Acting Injectable Risperidone Among Patients with Schizophrenia

Trial Profile

Cost-Consequence Analysis of Switching from an Oral Antipsychotic to Long Acting Injectable Risperidone Among Patients with Schizophrenia

Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Dec 2011

At a glance

  • Drugs Risperidone (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Acronyms SMART
  • Most Recent Events

    • 06 Dec 2011 New trial record
    • 08 Nov 2011 Results presented at the 14th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top